We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
VSTM

Price
6.65
Stock movement down
-0.17 (-2.49%)
Company name
Verastem Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
295.97M
Ent værdi
276.95M
Pris/omsætning
29.26
Pris/bog
9.19
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-20.58%
1 års afkast
-41.20%
3 års afkast
-22.92%
5 års afkast
-22.33%
10 års afkast
-25.67%
Senest opdateret: 2025-03-22

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UDBYTTE

VSTM betaler ikke udbytte

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning29.26
Pris til egenkapital9.19
EV i forhold til salg27.38

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier44.51M
EPS (TTM)-2.32
FCF pr. aktie (TTM)-2.72

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)10.11M
Bruttofortjeneste (TTM)10.10M
Driftsindkomst (TTM)-114.50M
Nettoindkomst (TTM)-93.45M
EPS (TTM)-2.32
EPS (1 år frem)-2.37

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)99.83%
Driftsmargin (TTM)-1132.14%
Fortjenstmargin (TTM)-924.01%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter113.17M
Nettotilgodehavender200.00K
Omsætningsaktiver i alt120.66M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr664.00K
Sum aktiver126.38M
Kreditor4.44M
Kortfristet/nuværende langsigtet gæld41.43M
Summen af kortfristede forpligtelser37.37M
Sum gæld94.16M
Aktionærernes egenkapital32.22M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-109.35M
Investeringsudgifter (TTM)35.00K
Fri pengestrøm (TTM)-109.39M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-290.06%
Afkast af aktiver-73.95%
Afkast af investeret kapital-126.89%
Kontant afkast af investeret kapital-148.53%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning6.71
Daglig høj6.79
Daglig lav6.26
Daglig volumen865K
Højeste gennem alle tider210.84
1 års analytiker estimat11.13
Beta0.14
EPS (TTM)-2.32
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation7 May 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
VSTMS&P500
Nuværende prisfald fra top notering-96.85%-7.99%
Højeste prisfald-98.96%-56.47%
Højeste efterår dato5 Aug 20249 Mar 2009
Gennemsnitlig fald fra toppen-73.30%-11.07%
Gennemsnitlig tid til nyt højdepunkt174 days12 days
Maks. tid til nyt højdepunkt2943 days1805 days

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
VSTM (Verastem Inc) company logo
Markedsværdi
295.97M
Markedsværdi kategori
Small-cap
Beskrivelse
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Personale
73
Investor relationer
-
SEC-indsendelser
Adm. direktør
Brian M. Stuglik
Land
USA
By
Needham
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...